DAIICHI SANKYO CO. LTD (D4S.DU)
| Previous close | 21.20 |
| Open | 21.41 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 21.34 - 21.41 |
| 52-week range | 15.20 - 27.67 |
| Volume | 50 |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.
- Reuters
AstraZeneca bets up to $6 billion on new Daiichi cancer drug
The British drugmaker has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate. AstraZeneca said on Monday it would make staggered upfront payments totalling $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC). The deal will not affect 2020 earnings forecast, AstraZeneca said.
- Business Wire
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
